CN114129479A

CN114129479A - Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof

Info

Publication number: CN114129479A
Application number: CN202111467494.0A
Authority: CN
Inventors: 高戎戎; 王海燕
Original assignee: Shanghai Ruyu Biotechnology Co ltd; Wozi Shanghai Biotechnology Co ltd
Current assignee: Shanghai Ruyu Biotechnology Co ltd; Wozi Shanghai Biotechnology Co ltd
Priority date: 2021-12-03
Filing date: 2021-12-03
Publication date: 2022-03-04

Abstract

The invention discloses a composition for effectively and rapidly relieving dry eczema of infants, and a preparation method and application thereof. Phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine; the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil; the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose. The invention also provides a preparation method and application of the composition. The composition is used for preparing infant cream. The composition prepared by the invention can effectively and quickly relieve dry eczema for all skins of infants.

Description

Composition for effectively and rapidly relieving infant dry eczema and preparation method and application thereof

Technical Field

The invention relates to a formula composition for effectively relieving infant eczema sicca in the field of cosmetics, a preparation method and application thereof, and particularly relates to a composition for effectively and quickly relieving infant eczema sicca, a preparation method and application thereof.

Background

In the growing process of babies, a father baby and a mother baby are worried about suffering from dry eczema. Eczema sicca is also known as fatty eczema and is mainly affected by factors such as familial heredity and seasonal factors. Wherein the family genetic factors are commonly found in infants; meanwhile, the skin is dried in autumn and winter, so that the skin is less nourished, the skin lipid film becomes thin, and the skin is dried and desquamated, and the dry eczema is formed. In addition, many infants have dry skin, desquamation, pruritus and other symptoms due to hypoevolutism of sebaceous glands or excessive bathing and insufficient secretion of oil.

For infants with dry eczema, dad should first avoid external stimulation, pay attention to the change of body temperature of the infants and pay attention to the change of air humidity. Meanwhile, the skin of the baby should be kept clean and dry, and the skin moisturizing lotion is adopted after bathing, so that the water-oil balance of the skin of the baby is improved. However, the skin moistening and moisturizing lotions on the market at present are uneven in level, the safety is difficult to guarantee, and a natural composition aiming at dry eczema is also lacked.

Disclosure of Invention

The invention aims to provide a formula composition suitable for infants to effectively relieve eczema sicca, a preparation method thereof and application of the formula composition in skin care products, which can solve the existing problems and effectively and quickly relieve eczema sicca for all skin types of infants.

In order to achieve the above object, the present invention provides a composition for effectively and rapidly relieving infantile eczema sicca, wherein the composition comprises a phase a, a phase B, a phase C; phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine; the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil; the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose.

The composition for effectively and rapidly relieving dry eczema of infants comprises the following components in parts by weight: phase A, 2.8-3.3 parts of glycerol, 2.8-3.3 parts of 1, 2-hexanediol, 0.04-0.08 part of carbomer and 0.8-1.2 parts of arginine; phase B, 4.5-5.4 parts of camellia oil, 2.8-3.3 parts of caprylic/capric triglyceride, 2.8-3.3 parts of polyglycerol-3-methyl glucose distearate, 2.8-3.3 parts of cetostearyl alcohol, 2.8-3.3 parts of palmitic acid, 1.6-2.2 parts of glycerol stearate citrate, 0.8-1.2 parts of glycerol stearate, 4.5-5.4 parts of tocopherol, namely vitamin E, and 4.5-5.4 parts of chinaroot greens seed oil; phase C, 4.5-5.4 parts of purslane extract, 2.8-3.3 parts of butanediol, 4.5-5.4 parts of phytosphingosine, 4.5-5.4 parts of cholesterol, 0.8-1.2 parts of sodium lauroyl lactylate, 4.5-5.4 parts of ethylhexyl glycerol, 4.5-5.4 parts of ceramide NP, 4.5-5.4 parts of ceramide EOP, 4.5-5.4 parts of ceramide AP, 4.5-5.4 parts of lecithin, 9.5-10.5 parts of boswellia serrata resin extract and 0.05-0.2 part of microcrystalline cellulose.

The composition for effectively and rapidly relieving dry eczema of infants is prepared by adding water to 100 parts by weight.

The composition for effectively and rapidly relieving infantile eczema sicca comprises the following components in percentage by mass: phase A, 3% of glycerol, 3% of 1, 2-hexanediol, 0.05% of carbomer and 1% of arginine; phase B, camellia seed oil 5%, caprylic/capric triglyceride 3%, polyglyceryl-3-methylglucose distearate 3%, cetearyl alcohol 3%, palmitic acid 3%, glyceryl stearate citrate 2%, glyceryl stearate 1%, tocopherol, i.e. vitamin E5%, meadowfoam seed oil 5%; phase C, purslane extract 5%, butylene glycol 3%, phytosphingosine 5%, cholesterol 5%, sodium lauroyl lactylate 1%, ethylhexylglycerin 5%, ceramide NP 5%, ceramide EOP 5%, ceramide AP 5%, lecithin 5%, boswellia serrata resin extract 10%, and microcrystalline cellulose 0.1%.

The composition for effectively and rapidly relieving dry eczema in infants is prepared by adding water to 100% by mass.

The invention also provides a preparation method of the composition for effectively and rapidly relieving infantile eczema sicca, wherein the method comprises the following steps: step 1, weighing raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C; step 2, heating the phase A to be completely dissolved; step 3, heating the phase B until the phase B is completely dissolved, adding the phase B into the phase A, and emulsifying; step 4, cooling the obtained mixture, adding the phase C, and uniformly stirring; and 5, continuously cooling to finish the preparation of the composition.

In the step 3, after the phase B is heated to be completely dissolved, the phase B is added into the phase A and emulsified for 5 minutes.

In the step 4, the mixture is cooled to 40 ℃, and then the phase C is added.

In the above preparation method of the composition for effectively and rapidly relieving infantile eczema, in the step 5, the mixture is continuously stirred and cooled to room temperature, so that the preparation of the composition is completed.

The invention also provides the application of the composition prepared by the method for effectively and rapidly relieving the dry eczema of the infant, wherein the composition is used for preparing a skin care product; the skin care product comprises baby cream.

The composition for effectively and rapidly relieving dry eczema of infants, the preparation method and the application provided by the invention have the following advantages:

the composition disclosed by the invention is prepared by combining BOSWELLIA SERRATA (BOSWELLIA SERRATA) resin extract, ceramide NP/ceramide EOP/ceramide AP, phytosphingosine/cholesterol composition, purslane (PORTULACA OLERACEA) extract, CAMELLIA (CAMELLIA JAPONICA) seed oil and the like for the first time. The obtained composition can effectively and rapidly relieve various symptoms of dryness, itching, damage, redness, stabbing pain, rash and the like caused by infant eczema sicca aiming at all skin types of infants, and rapidly repair skin barriers, thereby repairing the skin immune system of the infants.

The composition can rapidly improve symptoms such as sensitive roughness, acne, red blood streak, desquamation, pruritus and the like caused by dry skin, and has the effects of repairing skin barriers, supplementing water, moistening skin, moisturizing and locking water, relieving allergy, resisting inflammation, delaying aging and the like, thereby effectively relieving skin sensitive eczema, eliminating pox, reducing red blood streak, improving desquamation and the like.

Detailed Description

The following further describes embodiments of the present invention.

The composition for effectively and rapidly relieving the dry eczema in the infant comprises a phase A, a phase B and a phase C; phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine; the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil; the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose.

Preferably, the composition comprises the following components in parts by weight: phase A, 2.8-3.3 parts of glycerol, 2.8-3.3 parts of 1, 2-hexanediol, 0.04-0.08 part of carbomer and 0.8-1.2 parts of arginine; phase B, 4.5-5.4 parts of camellia oil, 2.8-3.3 parts of caprylic/capric triglyceride, 2.8-3.3 parts of polyglycerol-3-methyl glucose distearate, 2.8-3.3 parts of cetostearyl alcohol, 2.8-3.3 parts of palmitic acid, 1.6-2.2 parts of glycerol stearate citrate, 0.8-1.2 parts of glycerol stearate, 4.5-5.4 parts of tocopherol, namely vitamin E, and 4.5-5.4 parts of chinaroot greens seed oil; phase C, 4.5-5.4 parts of purslane extract, 2.8-3.3 parts of butanediol, 4.5-5.4 parts of phytosphingosine, 4.5-5.4 parts of cholesterol, 0.8-1.2 parts of sodium lauroyl lactylate, 4.5-5.4 parts of ethylhexyl glycerol, 4.5-5.4 parts of ceramide NP, 4.5-5.4 parts of ceramide EOP, 4.5-5.4 parts of ceramide AP, 4.5-5.4 parts of lecithin, 9.5-10.5 parts of boswellia serrata resin extract and 0.05-0.2 part of microcrystalline cellulose.

The composition is added with water to 100 parts by weight.

More preferably, the composition comprises the following components in percentage by mass: phase A, 3% of glycerol, 3% of 1, 2-hexanediol, 0.05% of carbomer and 1% of arginine; phase B, camellia seed oil 5%, caprylic/capric triglyceride 3%, polyglyceryl-3-methylglucose distearate 3%, cetearyl alcohol 3%, palmitic acid 3%, glyceryl stearate citrate 2%, glyceryl stearate 1%, tocopherol, i.e. vitamin E5%, meadowfoam seed oil 5%; phase C, purslane extract 5%, butylene glycol 3%, phytosphingosine 5%, cholesterol 5%, sodium lauroyl lactylate 1%, ethylhexylglycerin 5%, ceramide NP 5%, ceramide EOP 5%, ceramide AP 5%, lecithin 5%, boswellia serrata resin extract 10%, and microcrystalline cellulose 0.1%.

The composition is added with water to 100 percent by mass percent.

The main functional components of the composition of the invention are as follows: olibanum resin extract (Boswellia SERRATA), ceramide NP/ceramide EOP/ceramide AP, phytosphingosine/cholesterol composition, herba Portulacae (Portulaca OLERACEA) extract, and herba Camelliae Japonicae (Camellia JAPONICA) seed oil.

The BOSWELLIA SERRATA (BOSWELLIA SERRATA) resin extract is extracted from BOSWELLIA SERRATA resin, is a natural inflammation treatment substance, and can rapidly heal skin injury and repair skin barrier by activating a peroxidase to activate a receptor; promoting activation of caspase, prolonging skin cell life, and relieving cell aging. It has high safety and is widely used for pregnant women and infant products.

The ceramide NP/ceramide EOP/ceramide AP are various ceramide compounds, can be cooperated with natural protective barriers of the skin, can promote the water absorption of the skin, prevent the water loss of the skin and resist external influence, improve the autoimmune system, eliminate skin inflammation, have stronger oxidation resistance, and can relieve the symptoms of skin injury and the like.

Phytosphingosine/cholesterol compositions, in which phytosphingosine is a precursor to phospholipids, more closely related to skin lipids, are important components of moisture retention and barrier function. The phytosphingosine is one of important oil components in human epidermis, the reduction of the phytosphingosine can cause dry and rough skin, and the phytosphingosine can effectively keep the skin soft and moist and protect the cortex; phytosphingosine has antibacterial and antiinflammatory effects; cholesterol and derivatives thereof are inherent components of the skin, have no stimulation to the skin and have high safety; cholesterol has anti-inflammatory and moisturizing effects, and can promote absorption of effective components.

The herba Portulacae (Portulaca OLERACEA) extract contains abundant plant polysaccharides and vitamins, and has effects of moistening skin, promoting epithelial cell metabolism, and relieving desquamation and pruritus caused by dryness; simultaneously contains various amino acids, can shrink vascular smooth muscle, has the central and peripheral properties of contraction, and can relieve skin and inhibit skin pruritus caused by dryness; the herba Portulacae (Portulaca OLERACEA) extract also contains a large amount of alkaloids and flavones, and can be used for inhibiting bacteria and common pathogenic dermatophytes.

Camellia (Camellia JAPONICA) seed oil is extracted from CAMELLIA JAPONICA flower, leaf and seed, is natural component, has high safety, and can be used for pregnant women and infants. The camellia seed oil contains various unsaturated fatty acids, has good skin compatibility, is easy to be absorbed by the skin, contains more components such as tea polyphenol, camellia sesamin, tea saponin and the like, has extremely high vitamin E content and anti-inflammatory property, and can effectively treat skin problems such as allergy, rash, eczema and the like.

The invention also provides a preparation method of the composition for effectively and rapidly relieving the dry eczema of the infant, which comprises the following steps: step 1, weighing raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C; step 2, heating the phase A to be completely dissolved; step 3, heating the phase B until the phase B is completely dissolved, adding the phase B into the phase A, and emulsifying; step 4, cooling the obtained mixture, adding the phase C, and uniformly stirring; and 5, continuously cooling to finish the preparation of the composition.

In step 3, the phase B is heated to be completely dissolved, and then added into the phase A to be emulsified for 5 minutes.

In step 4, the mixture is cooled to 40 ℃ and then phase C is added.

And step 5, continuously stirring and cooling to room temperature to finish the preparation of the composition.

The invention also provides the application of the composition prepared by the method, which is used for preparing a skin care product and is effective in rapidly relieving infantile eczema sicca; the skin care product comprises baby cream.

The following examples are provided to further describe the composition for effectively and rapidly relieving infantile eczema sicca, the preparation method and the use thereof.

Example 1

A composition for effectively and rapidly relieving dry eczema in infants is shown in the following table 1.

All the raw materials respectively accord with the corresponding national standards.

Table 1 composition formulation table (in mass percent).

The embodiment also provides a preparation method of the composition for effectively and rapidly relieving infantile eczema sicca, which comprises the following steps:

step 1, weighing the raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C.

And 2, heating the phase A until the phase A is completely dissolved.

And 3, heating the phase B until the phase B is completely dissolved, adding the phase A into the phase B, and emulsifying for 5 minutes.

And 4, cooling the obtained mixture to 40 ℃, adding the phase C, and uniformly stirring.

And 5, continuously stirring and cooling to room temperature to finish the preparation of the composition.

The embodiment also provides the application of the composition prepared by the method, which is used for preparing the skin care product and is effective in rapidly relieving the dry eczema of the infant; the skin care product comprises baby cream.

Example 2

A composition for rapidly and effectively relieving infantile eczema sicca comprises phase A, phase B and phase C.

Preferably, the composition comprises the following components in parts by weight:

phase A, 2.8 parts of glycerol, 2.8 parts of 1, 2-hexanediol, 0.04 part of carbomer and 0.8 part of arginine.

Phase B, camellia seed oil 4.5 parts, caprylic/capric triglyceride 2.8 parts, polyglycerol-3-methylglucose distearate 2.8 parts, cetearyl alcohol 2.8 parts, palmitic acid 2.8 parts, glyceryl stearate citrate 1.6 parts, glyceryl stearate 0.8 part, tocopherol, namely vitamin E4.5 parts, and meadowfoam seed oil 4.5 parts.

Phase C, purslane extract 4.5 parts, butanediol 2.8 parts, phytosphingosine 4.5 parts, cholesterol 4.5 parts, sodium lauroyl lactylate 0.8 part, ethylhexyl glycerol 4.5 parts, ceramide NP 4.5 parts, ceramide EOP 4.5 parts, ceramide AP 4.5 parts, lecithin 4.5 parts, boswellia serrata resin extract 9.5 parts, and microcrystalline cellulose 0.05 part.

Further, water is added to the composition to 100 parts by weight.

And 2, heating the phase A until the phase A is completely dissolved.

Example 3

phase A, 3.3 parts of glycerol, 3.3 parts of 1, 2-hexanediol, 0.08 part of carbomer and 1.2 parts of arginine.

Phase B, camellia seed oil 5.4 parts, caprylic/capric triglyceride 3.3 parts, polyglycerol-3-methylglucose distearate 3.3 parts, cetearyl alcohol 3.3 parts, palmitic acid 3.3 parts, glyceryl stearate citrate 2.2 parts, glyceryl stearate 1.2 parts, tocopherol, namely vitamin E5.4 parts, and meadowfoam seed oil 5.4 parts.

Phase C, purslane extract 5.4 parts, butanediol 3.3 parts, phytosphingosine 5.4 parts, cholesterol 5.4 parts, sodium lauroyl lactylate 1.2 parts, ethylhexyl glycerol 5.4 parts, ceramide NP 5.4 parts, ceramide EOP 5.4 parts, ceramide AP 5.4 parts, lecithin 5.4 parts, boswellia serrata resin extract 10.5 parts, and microcrystalline cellulose 0.2 part.

Further, water is added to the composition to 100 parts by weight.

And 2, heating the phase A until the phase A is completely dissolved.

The compositions prepared in the examples were tested and evaluated in the following manner.

1. The person to be tested.

Experimental group (invention): 25, 12 men and 13 women; the age is 5-47 months.

Control group (placebo-general moisturizer): 25, 13 men and 12 women, age 4-46 months.

The data of sex, age, etc. of two groups of people are statistically processed, the difference is not statistically significant (P >0.05), and the two groups are comparable.

2. The use method comprises the following steps: the composition of each example of the invention was applied to the eczema sites of the experimental groups, the ordinary moisturizers were applied to the eczema sites of the control groups, and the skin repair time was recorded and evaluated as follows, and the occurrence of adverse reactions was recorded.

3. Evaluation criteria: the evaluation was made based on the condition of dry, itchy, damaged, red, prickled, rash, etc.

And (3) healing: the symptoms and signs are resolved by more than 95%.

The effect is shown: the clinical manifestation is reduced by 80 to 94 percent.

Improvement: clinical performance is reduced by 50-79%.

And (4) invalidation: no improvement in clinical manifestations.

4. As a result: the results are shown in table 2 below.

Table 2. experimental results.

The difference analysis (P is less than 0.05) of the experimental group and the control group has obvious difference, and the statistical significance is achieved. The effective rate of the experimental group is obviously higher than that of the control group, which shows that the experimental group can quickly and effectively relieve the symptoms of dryness, itching, breakage, redness, stabbing pain, rash and the like of the infant caused by the dry eczema, and various uncomfortable feelings can not be generated, thus the invention has good effect.

The composition for effectively and quickly relieving the dry eczema of the infants, the preparation method and the application can effectively and quickly relieve the dry eczema, relieve the skin sensitivity, improve the stable state of skin flora and effectively improve the symptoms of sensitive and rough skin, acne, red blood streak, desquamation, pruritus and the like aiming at all the skins of the infants.

In the components of the composition, the boswellia serrata resin extract has higher safety and can quickly heal skin injury and repair skin barriers; prolonging skin cell life, and relieving cell aging. The ceramide NP/ceramide EOP/ceramide AP can play a synergistic role with skin, promote water absorption, prevent water loss, resist external stimulation, improve an autoimmune system, eliminate skin inflammation and relieve skin injury. The phytosphingosine can keep skin soft and moist, protect cortex, and resist bacteria and inflammation; cholesterol and its derivatives are safe and non-irritating to the skin, have anti-inflammatory and moisturizing effects, and promote the absorption of active substances. The purslane extract can moisten skin, promote epithelial cell metabolism and relieve symptoms such as desquamation, pruritus and the like caused by dryness; contracting vascular smooth muscle and relieving skin pruritus; simultaneously has the functions of resisting bacteria and inhibiting common pathogenic dermatophytes. The camellia oil has high safety and anti-inflammatory property, and can effectively treat skin problems such as allergy, rash, eczema and the like.

The composition has high safety, can be used for pregnant women and infants, and can quickly relieve dryness of skin of infants, repair skin barrier, supplement water, moisten skin, keep moisture and lock water, relieve allergy and inflammation, and relieve pruritus, thereby effectively relieving skin sensitive eczema, eliminating pox, reducing red blood streak, and improving desquamation.

While the present invention has been described in detail with reference to the preferred embodiments, it should be understood that the above description should not be taken as limiting the invention. Various modifications and alterations to this invention will become apparent to those skilled in the art upon reading the foregoing description. Accordingly, the scope of the invention should be determined from the following claims.

Claims

1. A composition for effectively and rapidly relieving dry eczema in infants is characterized by comprising a phase A, a phase B and a phase C;

phase A comprises water, glycerol, 1, 2-hexanediol, carbomer, and arginine;

the phase B comprises camellia seed oil, caprylic/capric triglyceride, polyglycerol-3-methylglucose distearate, cetearyl alcohol, palmitic acid, glyceryl stearate citrate, glyceryl stearate, tocopherol (vitamin E), and white Potentilla seed oil;

the phase C comprises herba Portulacae extract, butanediol, phytosphingosine, cholesterol, sodium lauroyl lactylate, ethylhexyl glycerol, ceramide NP, ceramide EOP, ceramide AP, lecithin, mastic resin extract of folium Osmanthi Fragrantis, and microcrystalline cellulose.

2. The composition for effectively and rapidly relieving dry eczema in infants according to claim 1, wherein the composition comprises the following components in parts by weight:

phase A, 2.8-3.3 parts of glycerol, 2.8-3.3 parts of 1, 2-hexanediol, 0.04-0.08 part of carbomer and 0.8-1.2 parts of arginine;

phase B, 4.5-5.4 parts of camellia oil, 2.8-3.3 parts of caprylic/capric triglyceride, 2.8-3.3 parts of polyglycerol-3-methyl glucose distearate, 2.8-3.3 parts of cetostearyl alcohol, 2.8-3.3 parts of palmitic acid, 1.6-2.2 parts of glycerol stearate citrate, 0.8-1.2 parts of glycerol stearate, 4.5-5.4 parts of tocopherol, namely vitamin E, and 4.5-5.4 parts of chinaroot greens seed oil;

phase C, 4.5-5.4 parts of purslane extract, 2.8-3.3 parts of butanediol, 4.5-5.4 parts of phytosphingosine, 4.5-5.4 parts of cholesterol, 0.8-1.2 parts of sodium lauroyl lactylate, 4.5-5.4 parts of ethylhexyl glycerol, 4.5-5.4 parts of ceramide NP, 4.5-5.4 parts of ceramide EOP, 4.5-5.4 parts of ceramide AP, 4.5-5.4 parts of lecithin, 9.5-10.5 parts of boswellia serrata resin extract and 0.05-0.2 part of microcrystalline cellulose.

3. The composition for effectively and rapidly relieving dry eczema in infants according to claim 2, wherein the composition is prepared by adding water to 100 parts by weight.

4. The composition for effectively and rapidly relieving infantile eczema sicca according to claim 2, wherein the composition comprises the following components in percentage by mass:

phase A, 3% of glycerol, 3% of 1, 2-hexanediol, 0.05% of carbomer and 1% of arginine;

phase B, camellia seed oil 5%, caprylic/capric triglyceride 3%, polyglyceryl-3-methylglucose distearate 3%, cetearyl alcohol 3%, palmitic acid 3%, glyceryl stearate citrate 2%, glyceryl stearate 1%, tocopherol, i.e. vitamin E5%, meadowfoam seed oil 5%;

phase C, purslane extract 5%, butylene glycol 3%, phytosphingosine 5%, cholesterol 5%, sodium lauroyl lactylate 1%, ethylhexylglycerin 5%, ceramide NP 5%, ceramide EOP 5%, ceramide AP 5%, lecithin 5%, boswellia serrata resin extract 10%, and microcrystalline cellulose 0.1%.

5. The composition for effectively and rapidly relieving dry eczema in infants according to claim 4, wherein the composition is added with water to 100% by mass.

6. A method for preparing a composition for effectively and rapidly relieving dry eczema in infants according to any one of claims 1 to 5, wherein the method comprises the following steps:

step 1, weighing raw materials in proportion, and dividing the raw materials into a phase A, a phase B and a phase C;

step 2, heating the phase A to be completely dissolved;

step 3, heating the phase B until the phase B is completely dissolved, adding the phase B into the phase A, and emulsifying;

step 4, cooling the obtained mixture, adding the phase C, and uniformly stirring;

and 5, continuously cooling to finish the preparation of the composition.

7. The method for preparing the composition for effectively and rapidly relieving dry eczema in infants according to claim 6, wherein in the step 3, the phase B is heated to be completely dissolved, then is added into the phase A, and is emulsified for 5 minutes.

8. The method for preparing the composition for effectively and rapidly relieving dry eczema in infants according to claim 6, wherein in the step 4, the C phase is added after the mixture is cooled to 40 ℃.

9. The method for preparing the composition for effectively and rapidly relieving infantile eczema sicca according to claim 6, wherein in the step 5, the composition is prepared by continuously stirring and cooling to room temperature.

10. Use of a composition effective in rapidly relieving dry eczema in infants prepared by the method of claim 6, in the preparation of a skin care product; the skin care product comprises baby cream.